RRx-001

未知生产厂商

RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.

技术标识符

化学式: C₅H₆BrN₃O₅
CAS 编号: 925206-65-1
UNII ID: 7RPW6SU9SC

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

COMPOSITIONS AND METHODS FOR REDUCING ADVERSE SIDE EFFECTS IN CANCER TREATMENT
EP 4536222 A1申请人: EPICENTRX INC优先权: 2022
EP
US
WO
3 件公开
CO-CRYSTALS OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE AND METHODS
US 20260035346 A1申请人: EPICENTRX INC优先权: 2022
US
WO
2 件公开
COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONARY HYPERTENSION
US 20260248761 A1申请人: EPICENTRX INC优先权: 2022
US
WO
2 件公开
RRX-001 FOR MINIMIZING POST-INFARCT ADVERSE VENTRICULAR REMODELING AND COMPLICATIONS
US 20260248762 A1申请人: EPICENTRX INC优先权: 2022
US
WO
2 件公开
METHODS AND COMPOSITIONS UTILIZING RRx-001 FOR RADIOPROTECTION
CN 112165937 A申请人: EPICENTRX INC优先权: 2018
CN
2 件公开
Methods and compositions utilizing RRx-001 combination therapy for radioprotection
US 11510901 B2申请人: EPICENTRX INC优先权: 2019
US
2 件公开
一种细胞膜仿生二氧化钛纳米粒的药物组合物
CN 109646675 B申请人: 郑州大学优先权: 2019
CN
COMPOSITIONS AND METHODS FOR TREATMENT OF NAFLD AND NASH AND RELATED DYSLIPIDEMIAS
US 20250134858 A1申请人: EPICENTRX INC优先权: 2023
US
SYSTEMS AND METHODS TO IMPROVE EXERCISE TOLERANCE
US 20250288555 A1申请人: EPICENTRX INC优先权: 2023
US
Application of combination of decitabine and RRx-001 in treatment of glioma
CN 116763808 A申请人: ZHONGSHAN HOSPITAL FUDAN UNIV优先权: 2023
CN

药物